Antidote for botulism
肉毒杆菌中毒的解毒剂
基本信息
- 批准号:7862592
- 负责人:
- 金额:$ 20.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-06-10 至 2012-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcetylcholineAcuteAddressAffectAmino AcidsAntibodiesAntidotesAntitoxinsAttenuatedBindingBinding SitesBioterrorismBontoxilysinBotulinum Toxin Type ABotulinum ToxinsBotulismC-terminalCategoriesCell membraneCellsCenters for Disease Control and Prevention (U.S.)Cleaved cellClostridium botulinumComplexConfocal MicroscopyCulture MediaCytoplasmDisease ProgressionDrug KineticsExocytosisExposure toFoundationsGoalsGrantHydrolysisIntensive CareInterphase CellIntoxicationKineticsLengthLifeLightLinkLongevityMembraneMotor NeuronsMusMutateMutationNeuronsNeurotransmittersPC12 CellsParalysedPatientsPeptide HydrolasesPersonsPositioning AttributeProductionProteinsRecombinantsRespiratory ParalysisSerotypingSterile coveringsStructureTimeToxinVentilatorWestern BlottingWorkZincbotulinumcholinergic neurondisulfide bondeffective therapyinhibitor/antagonistmutantneuromuscularpresynapticpreventpublic health relevancereceptorreconstitutionresearch studysmall moleculetime usetrafficking
项目摘要
DESCRIPTION (provided by applicant): Background. The CDC category A bioterrorism agent, Clostridium botulinum neurotoxin (BoNT), is a zinc protease that cleaves proteins involved in presynaptic acetylcholine release thereby causing paralysis. The proteolytically active light chain of BoNT serotype A (BoNT/A) hydrolyzes SNAP-25. Paralysis caused by BoNT serotype A (BoNT/A) can last several months. Any effective treatment must not only gain entry to the affected neurons and inactivate toxin, but must address the fact that BoNT/A has an extremely long duration of action. Hypothesis. We propose that toxin lacking protease activity (iBoNT/A) will be an effective antidote to acute botulism because it should compete for the same substrate as BoNT/A (SNAP-25) without cleaving it and should have the same longevity as BoNT/A. iBoNT/A should enter neurons, localize to same structure on the cell membrane that appears to stabilize the light chain to give its extraordinary long duration of activity, and at high enough intracellular concentrations, displace active light chain, thereby promoting its degradation and re- constituting exocytosis.
Preliminary Studies. In recent experiments, we have demonstrated that recombinant BoNT/A light chain inactivated by the introduction of three mutations in the zinc coordination region (iBoNT/A-L) inhibits cleavage of SNAP-25 by native BoNT/A light chain.
Specific Aims. We propose to determine whether iBoNT/A can 1) block BoNT/A protease activity in neuronal cells, 2) shorten the duration of action of BoNT/A , and 3) attenuate effects of BoNT/A in mice.
Work Proposed. We will determine the inhibition kinetics of native BoNT/A-L activity by iBoNT/A-L and if SNAP-25 cleavage can be inhibited by addition of full length, nicked iBoNT/A to the culture medium of PC-12 cells transfected with BoNT/A-L. We will determine whether iBoNT/A fused to fluorescent protein localizes to PC-12 plasma membrane and colocalizes with SNAP-25 using confocal microscopy. We will examine whether iBoNT/A can inhibit SNAP-25 cleavage in cultured motor neurons given native BoNT/A. The duration of inhibi- tion in these non-dividing cells will be determined. We will determine whether iBoNT/A can attenuate lethality or paralysis by native botulinum serotype A in mice. PUBLIC HEALTH RELEVANCE: Clostridium botulinum neurotoxin (BoNT) is a CDC category A bioterrorism agent. A patient with BoNT sero- type A (BoNT/A) intoxication may spend several months on a ventilator due to respiratory muscle paralysis. Release of a single gram of BoNT could affect several thousand people, thereby crippling local ICUs. There is currently no treatment available that reverses BoNT-induced paralysis. The ultimate goal of these studies is to generate an effective antidote to BoNT/A intoxication.
描述(由申请人提供):背景。CDC A类生物恐怖剂,肉毒梭菌神经毒素(BoNT),是一种锌蛋白酶,其切割参与突触前乙酰胆碱释放的蛋白质,从而引起麻痹。BoNT血清型A(BoNT/A)的蛋白水解活性轻链水解SNAP-25。由BoNT血清型A(BoNT/A)引起的瘫痪可持续数月。任何有效的治疗不仅必须进入受影响的神经元和肉毒毒素,而且必须解决BoNT/A具有极长的作用持续时间的事实。假说.我们提出缺乏蛋白酶活性的毒素(iBoNT/A)将是急性肉毒中毒的有效解毒剂,因为它应该与BoNT/A(SNAP-25)竞争相同的底物而不切割它,并且应该具有与BoNT/A相同的寿命。iBoNT/A应该进入神经元,定位于细胞膜上的相同结构,其似乎稳定轻链以赋予其非常长的活性持续时间,并且在足够高的细胞内浓度下,置换活性轻链,从而促进其降解并重建胞吐作用。
初步研究。在最近的实验中,我们已经证明了通过在锌配位区中引入三个突变而失活的重组BoNT/A轻链(iBoNT/A-L)抑制天然BoNT/A轻链对SNAP-25的切割。
具体目标。我们建议确定iBoNT/A是否可以1)阻断神经元细胞中的BoNT/A蛋白酶活性,2)缩短BoNT/A的作用持续时间,以及3)减弱BoNT/A在小鼠中的作用。
工作建议。我们将确定iBoNT/A-L对天然BoNT/A-L活性的抑制动力学,以及SNAP-25切割是否可以通过向用BoNT/A-L转染的PC-12细胞的培养基中添加全长、有切口的iBoNT/A来抑制。我们将使用共聚焦显微镜确定与荧光蛋白融合的iBoNT/A是否定位于PC-12质膜并与SNAP-25共定位。我们将检查iBoNT/A是否可以抑制给予天然BoNT/A的培养运动神经元中的SNAP-25切割。将确定这些非分裂细胞中的增殖持续时间。我们将确定iBoNT/A是否可以减弱小鼠中天然肉毒杆菌血清型A的致死性或麻痹。公共卫生相关性:肉毒梭菌神经毒素(BoNT)是CDC A类生物恐怖主义制剂。由于呼吸肌麻痹,BoNT血清型A(BoNT/A)中毒的患者可能在呼吸机上花费数月。释放一克BoNT可能会影响数千人,从而使当地的ICU瘫痪。目前没有可用的治疗方法可以逆转BoNT诱导的瘫痪。这些研究的最终目标是产生BoNT/A中毒的有效解毒剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID Owen BEENHOUWER其他文献
DAVID Owen BEENHOUWER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID Owen BEENHOUWER', 18)}}的其他基金
Multi-Dimensional Outcome Prediction Algorithm for Hospitalized COVID-19 Patients
住院 COVID-19 患者的多维结果预测算法
- 批准号:
10447721 - 财政年份:2021
- 资助金额:
$ 20.64万 - 项目类别:
Multi-Dimensional Outcome Prediction Algorithm for Hospitalized COVID-19 Patients
住院 COVID-19 患者的多维结果预测算法
- 批准号:
10299344 - 财政年份:2021
- 资助金额:
$ 20.64万 - 项目类别:
Multi-Dimensional Outcome Prediction Algorithm for Hospitalized COVID-19 Patients
住院 COVID-19 患者的多维结果预测算法
- 批准号:
10656282 - 财政年份:2021
- 资助金额:
$ 20.64万 - 项目类别:
Enhancing the Delivery of Amphotericin B Across the Blood Brain Barrier for Treatment of Cryptococcal Meningoencephalitis
增强两性霉素 B 穿过血脑屏障的递送以治疗隐球菌性脑膜脑炎
- 批准号:
10265385 - 财政年份:2018
- 资助金额:
$ 20.64万 - 项目类别:
Enhancing the Delivery of Amphotericin B Across the Blood Brain Barrier for Treatment of Cryptococcal Meningoencephalitis
增强两性霉素 B 穿过血脑屏障的递送以治疗隐球菌性脑膜脑炎
- 批准号:
9898292 - 财政年份:2018
- 资助金额:
$ 20.64万 - 项目类别:
Enhancing the Delivery of Amphotericin B Across the Blood Brain Barrier for Treatment of Cryptococcal Meningoencephalitis
增强两性霉素 B 穿过血脑屏障的递送以治疗隐球菌性脑膜脑炎
- 批准号:
9446257 - 财政年份:2018
- 资助金额:
$ 20.64万 - 项目类别:
Antibody cytokine fusion proteins against Cryptococcus neoformans
新型隐球菌抗体细胞因子融合蛋白
- 批准号:
7383656 - 财政年份:2008
- 资助金额:
$ 20.64万 - 项目类别:
Antibody cytokine fusion proteins against Cryptococcus neoformans
新型隐球菌抗体细胞因子融合蛋白
- 批准号:
8015629 - 财政年份:2008
- 资助金额:
$ 20.64万 - 项目类别:
Antibody cytokine fusion proteins against Cryptococcus neoformans
新型隐球菌抗体细胞因子融合蛋白
- 批准号:
7767749 - 财政年份:2008
- 资助金额:
$ 20.64万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 20.64万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 20.64万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 20.64万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 20.64万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 20.64万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 20.64万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 20.64万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 20.64万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 20.64万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 20.64万 - 项目类别:
Operating Grants